ASCO 2023 | Developing novel guidelines for breast cancer with lymph node micro-metastasis

Nadeem Bilani, MD, Icahn School of Medicine at Mount Sinai, New York, NY, comments on the need for standardized treatment guidelines for managing breast cancer with lymph node micro-metastasis. In trials such as the RxPONDER trial (NCT01272037), only one in ten patients had lymph node micro-metastasis, and novel clinical trials are needed to assess a larger cohort of this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.